Data Standards and Interoperability in Antimicrobial Resistance Surveillance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-21

Quick Answer

• Adopt recognized AMR data standards such as NCBI Pathogen Detection, CLSI susceptibility testing formats, and WHO surveillance definitions to enable cross-laboratory comparison of MIC and genomic data.
• Map local laboratory terminologies and measurement units to standard ontologies before data integration, starting with organism identification, antimicrobial agent names, and MIC values.
• Recognize that no single standard captures all AMR data types, so harmonization requires documented decisions about breakpoint versions, quality metrics, and metadata completeness.

At a Glance

The Interoperability Problem in AMR Surveillance

Antimicrobial resistance surveillance depends on comparing susceptibility results and genomic features across laboratories, regions, and time periods. A laboratory that tests a clinical isolate and reports a minimum inhibitory concentration produces a single data point. When that data point must be compared with results from another facility using different equipment, different interpretive criteria, or different data entry conventions, the comparison becomes unreliable. The same bacterial species tested against the same antimicrobial agent can yield results that appear discordant simply because the underlying data were recorded in incompatible formats.

The World Health Organization defines antimicrobial resistance as a global health threat and emphasizes that effective surveillance requires standardized approaches to data collection and reporting. Without interoperability, resistance trends cannot be distinguished from artifacts of data handling. A reported increase in resistant isolates may reflect a true epidemiological shift or may result from a change in testing methodology, a revised breakpoint, or a modification in how laboratories record their results.

Interoperability operates at multiple levels. Technical interoperability concerns the file formats and transmission protocols used to exchange data. Semantic interoperability concerns the meaning of terms, such as whether two laboratories use the same definition for an intermediate susceptibility result. Organizational interoperability concerns the policies and procedures that govern data sharing between institutions. A complete solution for AMR data integration must address all three levels.

For laboratory professionals and bioinformaticians, the practical consequence is that data integration projects fail or produce misleading results when these interoperability layers are ignored. A researcher who downloads genomic data from one repository and susceptibility data from another may find that isolate identifiers do not match, that antimicrobial agent names are spelled differently, or that MIC values are recorded in different units. Each of these discrepancies requires resolution before meaningful analysis can proceed.

Core Data Standards and Their Scope

CLSI Standards for Susceptibility Testing

The Clinical and Laboratory Standards Institute publishes documents that define methods for antimicrobial susceptibility testing and criteria for interpreting results. These standards specify how to perform dilution and disk diffusion tests, what media and reagents to use, and how to categorize results as susceptible, intermediate, or resistant. Laboratories that follow CLSI methods produce MIC values that are technically comparable because the testing conditions are standardized.

The interpretive criteria, commonly called breakpoints, are revised periodically as new clinical and microbiological data become available. A result interpreted as susceptible under one edition of the standards may be interpreted as resistant under a later edition. For data interoperability, the specific edition of the standards used for interpretation must be recorded alongside the raw MIC value. A numeric MIC of 2 micrograms per milliliter has a fixed meaning, but its categorical interpretation depends on the breakpoint version applied.

CLSI standards also address quality control requirements. Laboratories must test reference strains with known susceptibility patterns to verify that their testing system performs correctly. The results of these quality control tests must fall within established ranges for the testing to be considered valid. When integrating data from multiple laboratories, the presence and results of quality control testing provide important context for assessing data reliability.

NCBI Pathogen Detection and Genomic Data

The National Center for Biotechnology Information operates the Pathogen Detection system, which collects bacterial whole-genome sequence data and analyzes them for resistance determinants and phylogenetic relationships. This system provides a standardized pipeline for processing raw sequence reads, identifying resistance genes, and clustering related isolates. Submission of sequence data to this system requires associated metadata, including organism identification, collection date, and geographic location.

The value of a centralized genomic surveillance system depends on the consistency of the data submitted. Laboratories that submit raw sequence reads instead of assembled contigs allow the centralized pipeline to apply uniform quality filtering and analysis parameters. This approach reduces the variability introduced when individual laboratories use different assembly tools or different resistance gene detection thresholds.

Genomic data alone cannot fully replace phenotypic susceptibility testing. A resistance gene may be present but not expressed, or a novel resistance mechanism may not be recognized by existing gene databases. The integration of genomic and phenotypic data provides a more complete picture, but only when both data types can be linked reliably through shared isolate identifiers.

WHO Surveillance Definitions

The World Health Organization provides definitions and frameworks for antimicrobial resistance surveillance at the global level. These definitions establish common terminology for describing resistance patterns and for categorizing surveillance data. Standardized case definitions ensure that a resistant isolate identified in one country can be compared with a resistant isolate identified in another country.

WHO surveillance frameworks also address the structure of surveillance systems, including which pathogens to monitor, which antimicrobial agents to test, and how to report aggregated data. These frameworks support national and regional surveillance programs that feed into global monitoring efforts. For data managers, the WHO definitions provide a reference vocabulary that can be used to harmonize locally collected data.

The limitation of WHO definitions is that they operate at a higher level of abstraction than laboratory data standards. A WHO definition of multidrug resistance may specify which antimicrobial categories must be tested, but it does not specify the technical details of how those tests are performed. Laboratory-level standards such as CLSI documents and genomic standards such as NCBI Pathogen Detection operate at the technical level where data are actually generated.

Mapping and Harmonizing MIC Data

Recording Raw Values and Interpretive Categories

The first step in harmonizing MIC data is to distinguish between the raw measured value and the interpretive category assigned to it. The raw MIC is the lowest concentration of an antimicrobial agent that inhibits visible growth of the organism under defined test conditions. This value is a continuous measurement, typically expressed in micrograms per milliliter. The interpretive category, whether susceptible, intermediate, or resistant, is derived from the raw value using breakpoint criteria.

For data integration purposes, the raw MIC value is more portable than the interpretive category. A raw value can be reinterpreted when breakpoints change, whereas a categorical result is locked to the breakpoint version in use at the time of testing. Laboratories that record only categorical results lose the ability to reanalyze their data under updated criteria.

When mapping MIC data from different sources, the following fields must be aligned:

Handling Censored Values

MIC testing produces censored values when the organism grows at the highest concentration tested or is inhibited at the lowest concentration tested. A result reported as greater than 16 micrograms per milliliter means that the organism was not inhibited at the highest concentration in the dilution series. A result reported as less than or equal to 0.03 micrograms per milliliter means that the organism was inhibited at the lowest concentration tested.

These censored values create challenges for data analysis. Treating a greater-than value as if it were exactly the reported concentration underestimates the true MIC. Treating a less-than-or-equal-to value as if it were exactly the reported concentration overestimates the true MIC. Statistical methods for survival analysis or interval-censored data can accommodate these values, but only when the censoring is explicitly recorded.

Data harmonization must preserve the distinction between exact values and censored values. A dataset that converts all greater-than values to the reported number loses information and introduces bias. The standard notation using greater-than and less-than symbols should be retained in the integrated dataset, and analysis methods should account for the censoring structure.

Breakpoint Version Management

Breakpoints change over time as new evidence accumulates. A laboratory that has been testing a particular organism-antimicrobial combination for many years may have results interpreted under several different breakpoint editions. For longitudinal surveillance, these results cannot be compared directly unless they are reinterpreted under a common breakpoint version.

Reinterpretation requires access to the raw MIC values. If only categorical results were recorded, reinterpretation is impossible. This is a strong argument for maintaining raw MIC data in laboratory information systems and for including raw values in data submissions to surveillance programs.

When breakpoints change, the practical decision is whether to reanalyze historical data or to restrict trend analysis to the period after the change. Reanalysis is preferable when raw values are available and when the computational resources exist to apply the new breakpoints. Restricting the analysis period is simpler but reduces the length of the surveillance record. The choice should be documented in the analysis methods and considered when interpreting trends.

Integrating Genomic and Phenotypic Data

Linking Isolates Across Data Types

Genomic and phenotypic data are generated through different workflows and often stored in different systems. A clinical isolate may have a susceptibility profile recorded in the laboratory information system and a genome sequence deposited in a public repository. Linking these data requires a shared identifier that is stable across both systems.

The isolate identifier used in the laboratory must be included in the metadata submitted with the genome sequence. Without this linkage, the genomic data cannot be associated with the phenotypic data. Some repositories require or encourage the inclusion of strain identifiers in the submission metadata, but the completeness of this information varies.

For retrospective integration, the linkage may need to be reconstructed from available information. Matching on organism species, collection date, and specimen source can identify likely matches, but this approach carries the risk of false matches. A documented matching procedure with explicit criteria and a manual review step is necessary to maintain data quality.

Resistance Gene Detection and Nomenclature

AMR databases provide the reference sequences and detection tools used to identify resistance determinants in genomic data. These databases differ in their content, their gene nomenclature, and their detection thresholds. A gene that is detected by one database may be missed by another, or the same gene may be reported under different names.

The review of antimicrobial resistance databases highlights both the opportunities and the challenges presented by these resources. Databases enable the identification of resistance determinants from sequence data and support the prediction of resistance profiles, but their differences must be understood when integrating results from multiple sources.

For harmonization, the specific database version and detection parameters used for each analysis should be recorded. When comparing results across studies, the same database version should be used, or the results should be cross-referenced to identify discrepancies. A resistance gene annotation is only meaningful when the detection method is known.

Predicting Resistance from Genomic Data

Genomic prediction of antimicrobial resistance uses the presence of known resistance genes and mutations to infer the likely phenotype. This approach is valuable for surveillance because it can be applied to large numbers of isolates more rapidly than phenotypic testing. However, prediction accuracy varies by organism and antimicrobial agent.

The relationship between genotype and phenotype is not always straightforward. A resistance gene may be present but not expressed under the conditions of phenotypic testing. A mutation may confer resistance in one genetic background but not in another. Novel resistance mechanisms may not be represented in the databases used for prediction.

For data integration, genomic predictions should be treated as a distinct data type from phenotypic results. Combining predicted and measured phenotypes in a single analysis requires careful handling of discordant cases. A predicted resistant result that is phenotypically susceptible may indicate a database gap, an expression issue, or a data linkage error. Each discordance should be investigated instead of resolved by assumption.

Practical Workflow for Data Integration

Step 1: Inventory Existing Data Sources

Begin by identifying all data sources that contain AMR-relevant information. These may include laboratory information systems, electronic health records, research databases, public repositories, and reference laboratory reports. For each source, document the data format, the fields captured, the time period covered, and the responsible data steward.

The inventory should also assess data quality. Are MIC values recorded as raw numbers or only as categorical interpretations? Are quality control results available? Is the breakpoint version documented? Are isolate identifiers consistent and unique? This assessment determines what harmonization is possible and what limitations will remain.

Step 2: Define the Target Schema

The target schema specifies how harmonized data will be structured. This schema should include fields for all data types that will be integrated, with defined value sets for categorical fields and defined units for numeric fields. The schema should also include metadata fields that document the provenance of each record, including the source system, the original identifier, and any transformations applied.

The target schema should be designed to accommodate the data that actually exist, not an idealized dataset. If some sources lack quality control data, the schema should allow these fields to be null instead of requiring values that cannot be provided. The schema should also be extensible to accommodate new data types as they become available.

Step 3: Develop Mapping Rules

Mapping rules translate data from source formats to the target schema. These rules address terminology differences, unit conversions, and value transformations. For example, a source that records antimicrobial agent names as brand names must be mapped to standard drug names. A source that records MIC values in milligrams per liter must be converted to micrograms per milliliter.

Mapping rules should be documented in a machine-readable format that can be applied consistently. The rules should also include exception handling procedures for values that do not conform to expected patterns. A value that cannot be mapped should be flagged for manual review instead of silently dropped or assigned a default value.

Step 4: Validate and Reconcile

After mapping, the integrated dataset must be validated to identify errors and inconsistencies. Validation checks include verifying that organism names are valid, that MIC values fall within plausible ranges, that categorical interpretations are consistent with the recorded breakpoints, and that isolate identifiers are unique.

Reconciliation is the process of resolving discrepancies between sources. A discrepancy may indicate a data entry error, a difference in testing methodology, or a genuine biological difference. The resolution of each discrepancy should be documented, and the documentation should be retained as part of the dataset provenance.

Step 5: Document and Maintain

Data integration is not a one-time activity. New data are generated continuously, and standards evolve over time. The mapping rules, target schema, and validation procedures must be maintained and updated as conditions change.

Documentation should include the version of each standard applied, the date of each mapping rule update, and the rationale for any changes. This documentation supports reproducibility and allows future analysts to understand the decisions that shaped the dataset.

Common Failure Patterns in AMR Data Integration

Loss of Raw Data

The most common and most damaging failure is the loss of raw MIC values. When only categorical interpretations are retained, the ability to reanalyze data under updated breakpoints is lost. This failure often occurs because laboratory information systems are configured to store only the final interpretation, or because data exports omit the raw values.

Prevention requires configuring systems to retain raw values and establishing data management policies that require their preservation. When historical data have already been lost, the limitation must be acknowledged in any analysis that depends on breakpoint reinterpretation.

Identifier Inconsistency

Isolate identifiers that are not unique, not stable, or not consistently recorded prevent the linkage of phenotypic and genomic data. A single isolate may have different identifiers in different systems, or the same identifier may be reused for different isolates.

Prevention requires a centralized identifier management system that assigns unique identifiers at the time of specimen collection and propagates those identifiers through all downstream systems. For retrospective integration, a documented matching procedure with manual review is necessary.

Terminology Drift

Terminology changes over time as new species are described, new antimicrobial agents are introduced, and new resistance mechanisms are characterized. A dataset that uses outdated terminology becomes increasingly difficult to integrate with newer data.

Prevention requires regular updates to mapping tables and the use of controlled vocabularies that are maintained by recognized standards organizations. When terminology changes, the mapping rules must be updated and the historical data must be re-examined for consistency.

Breakpoint Mixing

Datasets that contain results interpreted under different breakpoint versions without documentation of the version used for each result are effectively unusable for trend analysis. The categorical interpretations cannot be compared because they were derived using different criteria.

Prevention requires recording the breakpoint version for every result and reinterpreting historical data when breakpoints change. When reinterpretation is not possible, the analysis must be restricted to the period covered by a single breakpoint version.

Quality Control Gaps

Data from laboratories that do not perform adequate quality control testing cannot be distinguished from data from laboratories that do. A resistance trend may reflect differences in laboratory performance instead of genuine epidemiological changes.

Prevention requires that quality control results be recorded and submitted with surveillance data. The presence of quality control data provides a basis for assessing data reliability and for identifying laboratories that may need corrective action.

Biosafety and Data Handling Considerations

Laboratory work with antimicrobial-resistant organisms requires adherence to established biosafety practices. The Biosafety in Microbiological and Biomedical Laboratories publication from the CDC and NIH provides guidance on risk assessment, containment, and decontamination for work with infectious agents. The appropriate biosafety level depends on the organism being handled and the procedures being performed.

For data integration work, the biosafety considerations are primarily about the handling of clinical specimens and cultures before data are generated. Laboratory professionals who perform susceptibility testing and nucleic acid extraction must follow the containment practices appropriate for the organisms involved. The data themselves do not pose a biological risk, but the specimens from which they are derived do.

The American Society for Microbiology provides professional education and laboratory practice resources that support the training of laboratory personnel. Proper training in specimen handling, testing procedures, and data recording is essential for producing reliable AMR data. A laboratory that produces poor-quality data cannot compensate through data integration efforts downstream.

The FDA Bacteriological Analytical Manual provides official methods for food microbiology that include quality and method validation context. While this manual focuses on food testing, its emphasis on validated methods and quality assurance is relevant to any laboratory that generates AMR data for surveillance purposes.

Quality Controls and Reference Materials

Authenticated Reference Strains

The American Type Culture Collection maintains authenticated biological materials, including bacterial strains with documented characteristics. Reference strains with established MIC ranges are used for quality control of susceptibility testing. Testing these strains alongside clinical isolates verifies that the testing system is performing correctly.

For data integration, the results of reference strain testing provide a benchmark for assessing laboratory performance. A laboratory whose reference strain results fall outside established ranges produces data that cannot be trusted. The inclusion of reference strain results in surveillance data submissions supports data quality assessment.

Internal and External Quality Assessment

Internal quality assessment includes the routine testing of reference strains, the review of results by supervisory personnel, and the monitoring of trends in quality control data. External quality assessment involves the testing of unknown specimens provided by an external program and the comparison of results with those of other laboratories.

Both types of quality assessment generate data that are relevant to AMR surveillance. A laboratory that participates in external quality assessment and performs well produces data that can be compared with data from other laboratories with greater confidence. The results of quality assessment should be documented and considered when integrating data from multiple sources.

Quality Metrics for Integrated Data

The quality of an integrated AMR dataset can be assessed using several metrics. Completeness measures the proportion of records that have values for all required fields. Consistency measures the proportion of records that pass validation checks. Timeliness measures the delay between specimen collection and data availability.

These metrics should be calculated and reported as part of the data integration process. A dataset with high completeness but low consistency may require additional validation effort. A dataset with high consistency but low completeness may not support the intended analyses. The metrics provide a basis for deciding whether the dataset is fit for its intended purpose.

Limitations of Current Standards and Approaches

Standards Coverage Gaps

Existing standards do not cover all aspects of AMR data. CLSI standards address phenotypic testing but do not address genomic data formats. NCBI Pathogen Detection addresses genomic data but does not define standards for phenotypic data submission. WHO definitions address surveillance frameworks but not laboratory-level data details.

These gaps mean that data integration requires custom solutions that combine elements from multiple standards. The custom solutions must be documented and maintained, adding to the workload of data managers. The lack of a single comprehensive standard is a structural limitation of the current landscape.

Database Heterogeneity

The review of AMR databases notes that these resources differ in their content and their approaches to identifying resistance determinants. A researcher who uses multiple databases must reconcile the differences in gene nomenclature and detection thresholds. This reconciliation is time-consuming and may introduce errors.

The heterogeneity of AMR databases also affects the reproducibility of genomic analyses. A study that uses one database version may produce different results than a study that uses another version. The database version must be reported to enable comparison of results across studies.

Temporal and Geographic Variation

AMR data standards and interpretive criteria vary over time and across regions. A breakpoint that is current in one country may be outdated in another. A resistance gene nomenclature that is standard in one database may not be recognized by another.

These variations complicate the integration of data from different time periods and different geographic regions. The harmonization process must account for these variations, and the limitations must be acknowledged in the interpretation of results.

The Role of Emerging Technologies

Artificial intelligence approaches are being developed for the analysis of AMR data, including the prediction of resistance from genomic sequences and the identification of novel resistance mechanisms. These approaches depend on large, well-annotated datasets for training and validation. The quality of the training data determines the quality of the predictions.

The application of AI to AMR data also raises questions about interpretability and validation. A model that predicts resistance with high accuracy may not provide insight into the underlying biological mechanisms. The integration of AI predictions with traditional data requires careful validation to ensure that the predictions are reliable.

Records and Documentation Requirements

Minimum Data Elements

Every AMR data record should include a defined set of minimum data elements. These elements include the organism identification, the antimicrobial agent tested, the raw MIC value or disk diffusion result, the interpretive category, the breakpoint version, the testing method, and the date of testing. Additional elements such as specimen source, patient demographics, and geographic location support epidemiological analysis.

The minimum data elements should be defined in the target schema and enforced through validation procedures. Records that lack required elements should be flagged and either completed or excluded from analysis. The completeness of the minimum data elements should be reported as a quality metric.

Provenance Documentation

Provenance documentation records the origin and processing history of each data record. This documentation includes the source laboratory, the original identifier, the date of data entry, the date of any transformations, and the person or system that performed the transformations.

Provenance documentation supports the assessment of data reliability and the investigation of discrepancies. A record with complete provenance can be traced back to its source and the original testing can be reviewed if necessary. A record with incomplete provenance cannot be fully verified.

Version Control

Version control applies to the standards, databases, and software used in the data integration process. The version of each standard should be recorded, including the specific edition of CLSI documents, the release date of AMR databases, and the version of analysis software.

Version control also applies to the integrated dataset itself. Each version of the dataset should be archived, and changes between versions should be documented. This practice supports reproducibility and allows the impact of changes to be assessed.

Professional Escalation Criteria

When to Consult a Reference Laboratory

A laboratory should consider consulting a reference laboratory when it encounters results that cannot be interpreted with confidence. These situations include unusual resistance patterns, discrepancies between phenotypic and genomic results, and organisms that are difficult to identify. A reference laboratory can provide confirmatory testing and expert interpretation.

The decision to escalate should be documented, including the reason for the consultation and the outcome. This documentation contributes to the data record and supports the interpretation of the final results.

When to Report to Public Health Authorities

Laboratories that identify organisms with unusual resistance patterns or that are associated with suspected outbreaks should report to public health authorities. The reporting requirements vary by jurisdiction and by organism. The WHO provides context for the global surveillance of antimicrobial resistance and the importance of timely reporting.

The decision to report should be based on established criteria and should be made in consultation with the laboratory director or the responsible clinician. The report should include all relevant data, including the susceptibility profile, the genomic data if available, and the epidemiological context.

When to Update Standards and Procedures

Data managers should review their standards and procedures on a regular basis and update them when new standards are published or when new data types become available. The review should consider changes in CLSI breakpoints, updates to AMR databases, and new requirements from surveillance programs.

The update process should include a review of the impact on existing data. A change in breakpoints may require the reinterpretation of historical data. A change in database versions may require the reanalysis of genomic data. The impact assessment should be documented and the affected data should be updated accordingly.

Decision Framework for Selecting Harmonization Depth

Data integration projects fail when teams apply the same harmonization effort to every data source regardless of its intended use. A surveillance dataset built for quarterly public health reporting does not require the same depth of genomic annotation as a research dataset designed for novel resistance mechanism discovery. The harmonization depth decision framework below gives data managers a structured method for matching effort to analytical purpose.

Tier 1: Passive Aggregation

Tier 1 harmonization applies when the integrated dataset will support descriptive reporting only. This tier suits routine surveillance summaries, trend monitoring for common pathogens, and administrative reporting to oversight bodies. The analytical questions are limited to counts and proportions, such as the percentage of isolates resistant to a specific agent within a defined period.

For Tier 1, the minimum requirements are consistent organism names, standardized antimicrobial agent identifiers, and categorical interpretations aligned to a single breakpoint version. Raw MIC values should be retained in the dataset but do not require statistical treatment of censored values. Quality control results should be present as pass or fail flags without detailed analysis. Genomic data, when included, can be limited to resistance gene presence or absence calls from a single database version.

The mapping effort for Tier 1 focuses on terminology alignment. Source systems that use different organism names or drug abbreviations must be mapped to the target vocabulary. Records that cannot be mapped should be excluded and counted, with the exclusion rate reported as a data quality metric. This tier does not attempt to reconcile discrepancies between sources beyond flagging them for future review.

Tier 2: Analytical Harmonization

Tier 2 harmonization supports comparative analyses where statistical methods will be applied. This tier suits research studies, outbreak investigations, and longitudinal trend analyses that require confidence intervals or hypothesis testing. The analytical questions involve relationships between variables, such as the association between resistance patterns and specimen source or geographic region.

Tier 2 requires full treatment of censored MIC values using interval-censored methods. The dataset must distinguish exact values from greater-than and less-than-or-equal-to values, and the analysis plan must specify how censoring will be handled. Breakpoint version must be recorded for every record, and historical data must be reinterpreted under a common version when trends span breakpoint changes.

Genomic data in Tier 2 require documented database versions and detection parameters. Discordance between genomic predictions and phenotypic results must be investigated and resolved with documented decisions. The reconciliation process should produce a discrepancy log that records each discordant case, the investigation performed, and the resolution applied.

Tier 3: Research-Grade Integration

Tier 3 harmonization applies when the integrated dataset will support novel analyses, machine learning applications, or multi-omics integration. This tier suits studies investigating resistance mechanisms, developing predictive models, or combining genomic, transcriptomic, and phenotypic data. The analytical questions are exploratory and may not be fully defined at the outset.

Tier 3 requires complete provenance documentation for every record, including the full processing history from specimen collection through final analysis. Raw sequence reads must be retained alongside assembled contigs and resistance gene annotations. Multiple AMR databases should be cross-referenced, with discrepancies between databases documented and resolved. The dataset must support reanalysis under future breakpoint versions and database updates.

The mapping effort for Tier 3 includes the development of machine-readable mapping rules that can be versioned and audited. Every transformation applied to the data must be reproducible from the source records. The dataset should include a complete audit trail that allows any result to be traced back to its originating laboratory data.

Selecting the Appropriate Tier

The selection of harmonization depth should be made before data integration begins and documented in the project plan. The decision depends on the analytical questions the dataset must answer, the resources available for harmonization work, and the quality of the source data.

A practical assessment method uses three questions. First, what decisions will be made from this dataset? If the decisions are operational, such as whether to issue an alert or allocate resources, Tier 1 may suffice. If the decisions are scientific, such as whether a resistance mechanism is emerging, Tier 2 or Tier 3 is required. Second, what statistical methods will be applied? Methods that assume exact measurements require Tier 2 treatment of censored values. Third, what is the cost of a wrong answer? If a wrong answer could lead to a missed outbreak or an incorrect public health recommendation, the higher tier is justified.

The tier selection should be reviewed when the dataset is updated or when new data sources are added. A dataset that began as Tier 1 may need to move to Tier 2 if new analytical questions emerge. The review should be documented and the harmonization procedures updated accordingly.

Tier Transition Procedures

Moving from one tier to another requires specific procedures to maintain data integrity. When upgrading from Tier 1 to Tier 2, the team must verify that raw MIC values were retained in the source records. If only categorical interpretations were stored, the upgrade is impossible without returning to the original laboratory data.

When upgrading from Tier 2 to Tier 3, the team must verify that provenance documentation is complete. Records with incomplete provenance cannot be upgraded and must be excluded from the research-grade dataset. The exclusion should be documented and reported.

Downgrading from a higher tier to a lower tier is simpler but should still be documented. A Tier 3 dataset can be summarized to Tier 1 format for a specific reporting purpose, but the summary should not replace the original dataset. The full dataset should be archived and the summary clearly labeled as derived.

Common Tier Selection Errors

The most common error is applying Tier 1 harmonization to data that will be used for Tier 2 analyses. This error occurs when the analytical plan is not fully specified before integration begins. The result is a dataset that cannot support the intended statistical methods, requiring rework or abandonment of the analysis.

A second error is applying Tier 3 harmonization to data that only requires Tier 1 treatment. This error wastes resources and delays the availability of the dataset. The additional effort does not improve the answers to descriptive questions and may introduce unnecessary complexity.

A third error is failing to document the tier selection. Without documentation, future analysts cannot understand why certain harmonization decisions were made or whether the dataset is appropriate for their intended analyses. The tier selection should be recorded in the dataset documentation and referenced in any publications or reports that use the data.

Records for Tier Decisions

Each tier decision should be recorded with the date of the decision, the rationale, the person or group making the decision, and the analytical questions that drove the selection. The record should also note any assumptions about data quality or source system capabilities that influenced the decision.

When the tier is reviewed and changed, the review record should document the reason for the change, the impact on existing data, and the procedures applied to transition the dataset. These records form part of the dataset provenance and support the reproducibility of analyses conducted on the integrated data.

The tier decision framework provides a practical structure for allocating harmonization effort. By matching the depth of harmonization to the analytical purpose, data managers can avoid both the failure of under-harmonized data and the waste of over-harmonized data. The framework also supports communication with stakeholders by making the limitations of each dataset explicit and defensible.

Frequently Asked Questions

What is the difference between raw MIC values and interpretive categories?

Raw MIC values are the measured concentrations of an antimicrobial agent that inhibit bacterial growth under standardized testing conditions. Interpretive categories, such as susceptible, intermediate, or resistant, are derived from raw values using breakpoint criteria published by organizations like CLSI. Raw values are more useful for data integration because they can be reinterpreted when breakpoints change, while categorical results are locked to the breakpoint version in use at the time of testing.

Why do breakpoint versions matter for AMR data comparison?

Breakpoints are revised periodically as new clinical and microbiological evidence becomes available. A result interpreted as susceptible under one edition of the standards may be interpreted as resistant under a later edition. When comparing data across time periods, the breakpoint version must be recorded and accounted for, or apparent resistance trends may reflect changes in interpretive criteria instead of genuine epidemiological changes.

How can genomic resistance predictions be reconciled with phenotypic test results?

Genomic predictions and phenotypic results may disagree when a resistance gene is present but not expressed, when a novel resistance mechanism is not recognized by existing databases, or when there is a data linkage error. Discordant cases should be investigated individually instead of resolved by assumption. The specific database version and detection parameters used for genomic analysis should be recorded to support the reconciliation process.

What are censored MIC values and how should they be handled?

Censored MIC values occur when an organism grows at the highest concentration tested, reported as greater than a specified value, or is inhibited at the lowest concentration tested, reported as less than or equal to a specified value. These values should be preserved in their original notation instead of converted to exact numbers. Statistical methods that account for interval censoring should be used when analyzing datasets that contain censored values.

What minimum data elements should be recorded for each AMR test?

Each AMR test record should include organism identification, antimicrobial agent tested, raw MIC value or disk diffusion result, interpretive category, breakpoint version, testing method, and date of testing. Additional elements such as specimen source, patient demographics, and geographic location support epidemiological analysis. The specific minimum elements should be defined in the target schema for the integrated dataset.

How do AMR databases differ and why does this matter?

AMR databases differ in their content, gene nomenclature, and detection thresholds. A resistance gene detected by one database may be missed by another, or the same gene may be reported under different names. The database version and detection parameters should be recorded for each analysis, and the same version should be used when comparing results across studies.

What quality control measures support reliable AMR data?

Quality control measures include the routine testing of authenticated reference strains with documented MIC ranges, participation in external quality assessment programs, and the monitoring of quality control results over time. The results of quality control testing should be recorded and submitted with surveillance data to support the assessment of data reliability.

When should a laboratory escalate unusual AMR findings?

A laboratory should escalate findings when it encounters unusual resistance patterns, discrepancies between phenotypic and genomic results, or organisms that are difficult to identify. Consultation with a reference laboratory can provide confirmatory testing and expert interpretation. Reporting to public health authorities should follow established criteria and should include all relevant data.

Related Bacteriology Guides

• Salmonellosis in Poultry: Serovar Surveillance, Antimicrobial Resistance, and Egg Safety
• Antimicrobial Resistance in Livestock-Associated Staphylococcus aureus: Genomic Epidemiology and One Health Implications
• Biological Foundation Models for Antimicrobial Peptide Discovery in Veterinary Pathogens
• Aeromonas hydrophila in Aquaculture: Virulence Factors and Antimicrobial Resistance
• Swine Bacterial Diseases: Colibacillosis, UTI, and Antimicrobial Resistance

References and Further Reading

• Biosafety in Microbiological and Biomedical Laboratories. CDC and NIH.
• Microbiology Resources. American Society for Microbiology.
• Antimicrobial Resistance. World Health Organization.
• Bacteriological Analytical Manual. U.S. Food and Drug Administration.
• Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute.
• Culture Collections. American Type Culture Collection.
• NCBI Pathogen Detection. National Center for Biotechnology Information.
• Next-Generation Target Discovery in ESKAPE Pathogens: An AI-Driven Framework from Omics-Based to Systems-Level Modeling and Clinical Translation.. 2026.
• Antimicrobial resistance databases: opportunities and challenges for public health.. 2026.
• Combating Antibacterial Resistance: The Integrative Role of Artificial Intelligence in Bio-Based Product Development.. 2026.
• Methicillin-Resistant &lt,i&gt,Staphylococcus aureus&lt,/i&gt, (MRSA) and Vancomycin-Resistant Enterococci (VRE) in Nosocomial Infections: A Systematic Review of Resistance, Pathogenesis, and Clinical Management.. 2026.

This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.